Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1609

1.

Synaptotagmin 13 is neuroprotective across motor neuron diseases.

Nizzardo M, Taiana M, Rizzo F, Aguila Benitez J, Nijssen J, Allodi I, Melzi V, Bresolin N, Comi GP, Hedlund E, Corti S.

Acta Neuropathol. 2020 Feb 17. doi: 10.1007/s00401-020-02133-x. [Epub ahead of print]

PMID:
32065260
2.

Microbial, chemico-physical and volatile aromatic compounds characterization of Pitina PGI, a peculiar sausage-like product of North East Italy.

Iacumin L, Osualdini M, Bovolenta S, Boscolo D, Chiesa L, Panseri S, Comi G.

Meat Sci. 2020 Feb 6;163:108081. doi: 10.1016/j.meatsci.2020.108081. [Epub ahead of print]

PMID:
32062526
3.

Corrigendum: Clinical Features of Headache in Patients With Diagnosis of Definite Vestibular Migraine: The VM-Phenotypes Projects.

Teggi R, Colombo B, Albera R, Asprella Libonati G, Balzanelli C, Batuecas Caletrio A, Casani AP, Espinosa-Sanchez JM, Gamba P, Lopez-Escamez JA, Lucisano S, Mandalà M, Neri G, Nuti D, Pecci R, Russo A, Martin-Sanz E, Sanz R, Tedeschi G, Torelli P, Vannucchi P, Comi G, Bussi M.

Front Neurol. 2020 Jan 24;10:1374. doi: 10.3389/fneur.2019.01374. eCollection 2019.

4.

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.

Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, Calderini E, D'Angelo G, Chidini G, Prandi E, Ricci G, Siciliano G, Bresolin N, Comi GP, Corti S, Magri F, Govoni A.

J Cell Mol Med. 2020 Feb 7. doi: 10.1111/jcmm.14939. [Epub ahead of print]

5.

Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis.

Pisa M, Chieffo R, Giordano A, Gelibter S, Comola M, Comi G, Leocani L.

Clin Neurophysiol. 2020 Feb;131(2):401-405. doi: 10.1016/j.clinph.2019.11.024. Epub 2019 Dec 10.

PMID:
31869704
6.

Herpes Simplex virus type 2 myeloradiculitis with a pure motor presentation in a liver transplant recipient.

Abati E, Gagliardi D, Velardo D, Meneri M, Conte G, Cinnante C, Bresolin N, Comi G, Corti S.

Transpl Infect Dis. 2019 Dec 23:e13236. doi: 10.1111/tid.13236. [Epub ahead of print]

PMID:
31868290
7.

No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a.

Freedman MS, Comi G, Coyle PK, Aldridge J, Chen L, Marhardt K, Kappos L.

Mult Scler Relat Disord. 2019 Dec 9;39:101891. doi: 10.1016/j.msard.2019.101891. [Epub ahead of print]

8.

A new electrophysiological non-invasive method to assess retinocortical conduction time in the Dark Agouti rat through the simultaneous recording of electroretinogram and visual evoked potential.

d'Isa R, Castoldi V, Marenna S, Santangelo R, Comi G, Leocani L.

Doc Ophthalmol. 2019 Dec 12. doi: 10.1007/s10633-019-09741-3. [Epub ahead of print]

PMID:
31832898
9.

Structural and functional disconnections convey the pathology progression along the Alzheimer's continuum.

Filippi M, Basaia S, Canu E, Imperiale F, Magnani G, Falautano M, Comi G, Falini A, Agosta F.

Mol Psychiatry. 2020 Jan;25(1):1. doi: 10.1038/s41380-019-0612-0. No abstract available.

PMID:
31827244
10.

Spinal muscular atrophy with respiratory distress type 1: Clinical phenotypes, molecular pathogenesis and therapeutic insights.

Saladini M, Nizzardo M, Govoni A, Taiana M, Bresolin N, Comi GP, Corti S.

J Cell Mol Med. 2020 Jan;24(2):1169-1178. doi: 10.1111/jcmm.14874. Epub 2019 Dec 4. Review.

11.

MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients.

Brogna C, Cristiano L, Verdolotti T, Pichiecchio A, Cinnante C, Sansone V, Sconfienza LM, Berardinelli A, Garibaldi M, Antonini G, Pane M, Pera MC, Antonaci L, Ficociello L, Albamonte E, Tasca G, Begliuomini C, Tartaglione T, Maggi L, Govoni A, Comi G, Colosimo C, Mercuri E.

J Neurol. 2019 Nov 27. doi: 10.1007/s00415-019-09646-w. [Epub ahead of print]

PMID:
31776722
12.

Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy.

Galimberti V, Tironi R, Lerario A, Scali M, Del Bo R, Rodolico C, Brizzi T, Gibertini S, Maggi L, Mora M, Toscano A, Comi GP, Sciacco M, Moggio M, Peverelli L.

Eur J Neurol. 2019 Nov 26. doi: 10.1111/ene.14131. [Epub ahead of print]

PMID:
31769567
13.

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.

Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610. [Epub ahead of print]

PMID:
31762387
14.

Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology.

Genchi A, Schwarz G, Semerano A, Callea M, Sanvito F, Simionato F, Panni P, Scomazzoni F, Doglioni C, Comi G, Falini A, Ancona F, Filippi M, Roveri L, Bacigaluppi M.

J Neurol Sci. 2020 Jan 15;408:116573. doi: 10.1016/j.jns.2019.116573. Epub 2019 Nov 7. No abstract available.

PMID:
31731112
15.

Molecular Approaches for the Treatment of Pompe Disease.

Bellotti AS, Andreoli L, Ronchi D, Bresolin N, Comi GP, Corti S.

Mol Neurobiol. 2020 Feb;57(2):1259-1280. doi: 10.1007/s12035-019-01820-5. Epub 2019 Nov 12. Review.

PMID:
31713816
16.

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.

Wiendl H, Carraro M, Comi G, Izquierdo G, Kim HJ, Sharrack B, Tornatore C, Daizadeh N, Chung L, Jacobs AK, Hogan RJ, Wychowski LV, Van Wijmeersch B; CARE-MS I, CARE-MS II, and CAMMS03409 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 29;7(1). pii: e635. doi: 10.1212/NXI.0000000000000635. Print 2020 Jan.

17.

Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials.

Lorenzano S, Vestri A, Bovi P, Cappellari M, Stanzione P, Samà D, Bruscoli M, Cavazzuti M, Zini A, Rasura M, Beccia M, Comi G, Sessa M, Gandolfo C, Balestrino M, Agnelli G, Caso V, Gerbino Promis P, Pozzessere C, Anticoli S, Perini F, Marcon M, Vinattieri A, Caruso A, Magoni M, Furlan M, Orlandi G, Di Lazzaro V, Valente M, Nencini P, Toni D.

Int J Stroke. 2019 Oct 26:1747493019884525. doi: 10.1177/1747493019884525. [Epub ahead of print]

PMID:
31657284
18.

Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.

Matà S, Ambrosini S, Saccomanno D, Biagioli T, Carpo M, Amantini A, Giannini F, Barilaro A, Toscani L, Del Mastio M, Comi GP, Sorbi S.

Neurol Sci. 2020 Feb;41(2):365-372. doi: 10.1007/s10072-019-04089-7. Epub 2019 Oct 25.

PMID:
31654362
19.

Italian consensus on treatment of spasticity in multiple sclerosis.

Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S; Italian Consensus Group on treatment of spasticity in multiple sclerosis.

Eur J Neurol. 2020 Mar;27(3):445-453. doi: 10.1111/ene.14110. Epub 2019 Dec 3.

PMID:
31652369
20.

Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.

Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira À, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Bisecco A, Gass A, Eisele P, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Comi G, Filippi M; MAGNIMS Study Group.

Neurology. 2019 Nov 12;93(20):e1852-e1866. doi: 10.1212/WNL.0000000000008466. Epub 2019 Oct 14.

PMID:
31611336
21.

Loss of the nucleoporin Aladin in central nervous system and fibroblasts of Allgrove Syndrome.

Bitetto G, Ronchi D, Bonato S, Pittaro A, Compagnoni GM, Bordoni A, Salani S, Frattini E, Lopez G, Cribiù FM, Corti S, Comi GP, Bresolin N, Di Fonzo A.

Hum Mol Genet. 2019 Dec 1;28(23):3921-3927. doi: 10.1093/hmg/ddz236.

22.

Changes in cortical motor outputs after a motor relapse of multiple sclerosis.

Chieffo R, Straffi L, Inuggi A, Coppi E, Moiola L, Martinelli V, Comi G, Leocani L.

Mult Scler J Exp Transl Clin. 2019 Sep 25;5(3):2055217319866480. doi: 10.1177/2055217319866480. eCollection 2019 Jul-Sep.

23.

Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.

Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M.

J Neurol. 2019 Dec;266(12):3163-3166. doi: 10.1007/s00415-019-09562-z. Epub 2019 Oct 4. No abstract available.

PMID:
31586260
24.

Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.

Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register.

J Neurol. 2019 Dec;266(12):3098-3107. doi: 10.1007/s00415-019-09531-6. Epub 2019 Sep 18.

PMID:
31535270
25.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.

PMID:
31492652
26.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.

PMID:
31492651
27.

Novel mutations in DNA2 associated with myopathy and mtDNA instability.

Ronchi D, Liu C, Caporali L, Piga D, Li H, Tagliavini F, Valentino ML, Ferrò MT, Bini P, Zheng L, Carelli V, Shen B, Comi GP.

Ann Clin Transl Neurol. 2019 Sep;6(9):1893-1899. doi: 10.1002/acn3.50888. Epub 2019 Sep 2.

28.

Cardiac and Neuromuscular Features of Patients with LMNA-Related Cardiomyopathy.

Peretto G, Di Resta C, Perversi J, Forleo C, Maggi L, Politano L, Barison A, Previtali SC, Carboni N, Brun F, Pegoraro E, D'Amico A, Rodolico C, Magri F, Manzi RC, Palladino A, Isola F, Gigli L, Mongini TE, Semplicini C, Calore C, Ricci G, Comi GP, Ruggiero L, Bertini E, Bonomo P, Nigro G, Resta N, Emdin M, Favale S, Siciliano G, Santoro L, Sinagra G, Limongelli G, Ambrosi A, Ferrari M, Golzio PG, Bella PD, Benedetti S, Sala S; Italian Network for Laminopathies (NIL).

Ann Intern Med. 2019 Sep 3. doi: 10.7326/M18-2768. [Epub ahead of print]

PMID:
31476771
29.

Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis.

Acquaviva M, Bassani C, Sarno N, Dalla Costa G, Romeo M, Sangalli F, Colombo B, Moiola L, Martinelli V, Comi G, Farina C.

Front Immunol. 2019 Aug 14;10:1922. doi: 10.3389/fimmu.2019.01922. eCollection 2019.

30.

Ophthalmoplegia Due to Miller Fisher Syndrome in a Patient With Myasthenia Gravis.

Brusa R, Faravelli I, Gagliardi D, Magri F, Cogiamanian F, Saccomanno D, Cinnante C, Mauri E, Abati E, Bresolin N, Corti S, Comi GP.

Front Neurol. 2019 Aug 13;10:823. doi: 10.3389/fneur.2019.00823. eCollection 2019.

31.

Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.

Preziosa P, Rocca MA, Riccitelli GC, Moiola L, Storelli L, Rodegher M, Comi G, Signori A, Falini A, Filippi M.

Neurotherapeutics. 2020 Jan;17(1):208-217. doi: 10.1007/s13311-019-00781-w.

PMID:
31452082
32.

Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature.

Gagliardi D, Meneri M, Saccomanno D, Bresolin N, Comi GP, Corti S.

Int J Mol Sci. 2019 Aug 25;20(17). pii: E4152. doi: 10.3390/ijms20174152. Review.

33.

CSF transplantation of a specific iPSC-derived neural stem cell subpopulation ameliorates the disease phenotype in a mouse model of spinal muscular atrophy with respiratory distress type 1.

Forotti G, Nizzardo M, Bucchia M, Ramirez A, Trombetta E, Gatti S, Bresolin N, Comi GP, Corti S.

Exp Neurol. 2019 Nov;321:113041. doi: 10.1016/j.expneurol.2019.113041. Epub 2019 Aug 21.

PMID:
31445043
34.

Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis.

Rintala A, Matcham F, Radaelli M, Locafaro G, Simblett S, Barattieri di San Pietro C, Bulgari V, Burke P, Devonshire J, Weyer J, Wykes T, Comi G, Hotopf M, Myin-Germeys I; on the behalf of the RADAR-CNS Consortium.

J Psychosom Res. 2019 Sep;124:109761. doi: 10.1016/j.jpsychores.2019.109761. Epub 2019 Jul 5. Review.

PMID:
31443806
35.

Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy.

Campagnolo M, Ruiz M, Falzone YM, Ermani M, Bianco M, Martinelli D, Cerri F, Quattrini A, Salvalaggio A, Castellani F, Comi G, Giannini F, Nobile-Orazio E, Fazio R, Riva N, Briani C.

J Peripher Nerv Syst. 2019 Sep;24(3):276-282. doi: 10.1111/jns.12342. Epub 2019 Aug 26.

PMID:
31397934
36.

Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.

Pisa M, Ratti F, Vabanesi M, Radaelli M, Guerrieri S, Moiola L, Martinelli V, Comi G, Leocani L.

Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603. [Epub ahead of print]

PMID:
31392924
37.

Activity evaluation of pure and doped zinc oxide nanoparticles against bacterial pathogens and Saccharomyces cerevisiae.

Zanet V, Vidic J, Auger S, Vizzini P, Lippe G, Iacumin L, Comi G, Manzano M.

J Appl Microbiol. 2019 Nov;127(5):1391-1402. doi: 10.1111/jam.14407. Epub 2019 Sep 2.

PMID:
31386785
38.

Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.

Brogna C, Coratt G, Pane M, Ricotti V, Messina S, D'Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E; on behalf on the International DMD group.

PLoS One. 2019 Jul 31;14(7):e0220714. doi: 10.1371/journal.pone.0220714. eCollection 2019.

39.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5):e591. doi: 10.1212/NXI.0000000000000591. eCollection 2019 Sep.

40.

The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.

Santangelo R, Dell'Edera A, Sala A, Cecchetti G, Masserini F, Caso F, Pinto P, Leocani L, Falautano M, Passerini G, Martinelli V, Comi G, Perani D, Magnani G.

Curr Alzheimer Res. 2019;16(7):587-595. doi: 10.2174/1567205016666190725150836.

PMID:
31345148
41.

In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis.

Vabanesi M, Pisa M, Guerrieri S, Moiola L, Radaelli M, Medaglini S, Martinelli V, Comi G, Leocani L.

Sci Rep. 2019 Jul 17;9(1):10371. doi: 10.1038/s41598-019-46251-3.

42.

Non-invasive visual evoked potentials to assess optic nerve involvement in the dark agouti rat model of experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein.

Castoldi V, Marenna S, d'Isa R, Huang SC, De Battista D, Chirizzi C, Chaabane L, Kumar D, Boschert U, Comi G, Leocani L.

Brain Pathol. 2020 Jan;30(1):137-150. doi: 10.1111/bpa.12762. Epub 2019 Jul 28.

PMID:
31267597
43.

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.

Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E; on behalf on the International DMD group.

PLoS One. 2019 Jun 25;14(6):e0218683. doi: 10.1371/journal.pone.0218683. eCollection 2019. Erratum in: PLoS One. 2019 Jul 31;14(7):e0220714.

44.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis.

Peroni S, Sorosina M, Malhotra S, Clarelli F, Osiceanu AM, Ferrè L, Roostaei T, Rio J, Midaglia L, Villar LM, Álvarez-Cermeño JC, Guaschino C, Radaelli M, Citterio L, Lechner-Scott J, Spataro N, Navarro A, Martinelli V, Montalban X, Weiner HL, de Jager P, Comi G, Esposito F, Comabella M, Martinelli-Boneschi F.

Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428. [Epub ahead of print]

PMID:
31221001
45.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

46.

Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".

Dalla Costa G, Martinelli V, Furlan R, Comi G.

Ann Neurol. 2019 Aug;86(2):324. doi: 10.1002/ana.25526. Epub 2019 Jun 26. No abstract available.

PMID:
31187511
47.

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.

Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS.

Mult Scler. 2019 Jun 7:1352458519851981. doi: 10.1177/1352458519851981. [Epub ahead of print]

PMID:
31172849
48.

Expanding the spectrum of genes responsible for hereditary motor neuropathies.

Previtali SC, Zhao E, Lazarevic D, Pipitone GB, Fabrizi GM, Manganelli F, Mazzeo A, Pareyson D, Schenone A, Taroni F, Vita G, Bellone E, Ferrarini M, Garibaldi M, Magri S, Padua L, Pennisi E, Pisciotta C, Riva N, Scaioli V, Scarlato M, Tozza S, Geroldi A, Jordanova A, Ferrari M, Molineris I, Reilly MM, Comi G, Carrera P, Devoto M, Bolino A.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1171-1179. doi: 10.1136/jnnp-2019-320717. Epub 2019 Jun 5.

PMID:
31167812
49.

Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis.

Dalla Costa G, Romeo M, Esposito F, Sangalli F, Colombo B, Radaelli M, Moiola L, Comi G, Martinelli V.

Mult Scler Relat Disord. 2019 Aug;33:75-77. doi: 10.1016/j.msard.2019.05.010. Epub 2019 May 21.

PMID:
31158806
50.

Prospects for the Use of Whey for Polyhydroxyalkanoate (PHA) Production.

Amaro TMMM, Rosa D, Comi G, Iacumin L.

Front Microbiol. 2019 May 9;10:992. doi: 10.3389/fmicb.2019.00992. eCollection 2019. Review.

Supplemental Content

Support Center